



*10/6/01*  
10/6/01  
RECEIVED  
Docket No. 157-47577-C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re application of: W. Marasco, et al.

OCT 05 2001

Serial No.: 09/522,727

Group No.: 1644

TECH CENTER 1600/2900

Filed: March 10, 2000

Examiner Roark, J.

For: INTRABODY-MEDIATED CONTROL OF IMMUNE REACTIONS

**RESTRICTION REQUIREMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In response to the Restriction Requirement dated August 2, 2001, a Petition for a One Month Extension of Time and payment of fee is enclosed. Applicants elect Species G, a component of the pathway involving MHC Class I, and subspecies i) MHC Class I  $\alpha$  chain, with traverse.

**REMARKS**

Applicants have previously elected Group I (directed to claims 1-5 and 7-12) in response to the Restriction Requirement. Applicants have now elected Species G, a component of the pathway involving MHC Class I, and subspecies i) MHC Class I  $\alpha$  chain, with traverse, on the grounds that examining all of the target molecules at the same time does not present an undue burden in these claims. The Examiner has issued the second restriction requirement in response to the Preliminary Amendment filed March 28, 2001. The amendment to claim 7 was amended to more particularly claim the elected invention and did not expand its scope.

In view of the foregoing, applicant respectfully submits that all claims are in condition for allowance. Early and favorable action is requested.

In the event that any additional fees are required, the PTO is authorized to charge our deposit account No. 50-0850.



Date: 9/25/01

Respectfully submitted,

Ronald I. Eisenstein

Ronald I. Eisenstein  
(Reg. No.: 30,628)  
NIXON PEABODY LLP  
101 Federal Street  
Boston, MA 02110  
(617) 345-6054